Figure 1

ARHI re-expression in breast cancer cells. (A) SKBr3 cells were transfected with pcDNA3-ARHI or pcDNA3 vector constructs. Lipofectamine alone was used as a negative control. The ARHI expression was detected by western blot. (B) MDA-MB-231 cells and (C) SKBr3 cells were treated with DAC, TSA or a combination of DAC and TSA. The untreated cells and cells treated with DMSO diluent were used as negative controls. The ARHI mRNA was detected by real-time quantitative RT-PCR and is presented as the fold change compared to the negative control. *P < 0.05 or ***P < 0.001 compared to the DMSO diluent controls. The data were obtained from three independent experiments. (D) ARHI expression in MDA-MB-231 xenografts was detected by real-time quantitative RT-PCR. It is presented as the fold change compared to the PBS control. Each group included xenografts from two mice, and the data were replicated in three independent experiments. **P < 0.01 compared to pcDNA3 vector/liposomes control.